View Older Stories View More Recent Stories

May 7, 2024 08:30AM Mirum Pharmaceuticals (MIRM) Announces Publication of Phase 3 MARCH Data
May 7, 2024 08:30AM Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC
May 1, 2024 04:10PM Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
Apr 10, 2024 09:30PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 2, 2024 08:33AM Mirum Pharmaceuticals' (MIRM) LIVMARLI Receives Positive Reimbursement Recommendation by Canada’s CADTH
Apr 2, 2024 08:30AM Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
Mar 13, 2024 06:01PM Mirum Pharmaceuticals (MIRM) Announces FDA Approval of LIVMARLI
Mar 13, 2024 06:00PM Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
Mar 8, 2024 07:30PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 5, 2024 08:00AM Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Feb 29, 2024 08:33AM Mirum Pharmaceuticals (MIRM) Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI
Feb 29, 2024 08:30AM Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI
Feb 28, 2024 04:03PM Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
Feb 21, 2024 04:05PM Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024
Feb 9, 2024 09:15PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 19, 2024 09:30PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 16, 2024 08:31AM Mirum Pharmaceuticals (MIRM) Appoints Joanne Quan as Chief Medical Officer
Jan 16, 2024 08:30AM Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer
Jan 10, 2024 07:00PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 8, 2024 08:35AM Mirum Pharmaceuticals (MIRM) Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates
Jan 8, 2024 08:30AM Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates
Jan 3, 2024 08:45AM Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Dec 18, 2023 08:30AM Mirum Pharmaceuticals, Inc. (MIRM) Announces Data from EMBARK Phase 2b Study
Dec 18, 2023 08:30AM Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia
Dec 8, 2023 07:30PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 20, 2023 04:05PM Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference
Nov 13, 2023 02:00PM Mirum Pharmaceuticals Presents New Data at The Liver Meeting®
Nov 10, 2023 05:30PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 3, 2023 08:30AM Mirum Pharmaceuticals to Present at the 2023 UBS Biopharma Conference
Nov 2, 2023 04:05PM Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
Oct 30, 2023 08:30AM Mirum Pharmaceuticals to Present New Data at The Liver Meeting®
Oct 27, 2023 08:45AM Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023
Oct 17, 2023 04:30PM Mirum Pharmaceuticals (MIRM) Announces Extension of PDUFA Date for LIVMARLI to March 13, 2024
Oct 17, 2023 04:30PM Mirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis
Oct 10, 2023 08:00PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 7, 2023 05:00PM Mirum Pharmaceuticals Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN
Oct 2, 2023 08:31AM Mirum Pharmaceuticals (MIRM) Announces Positive Phase 3 RESTORE Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis
Oct 2, 2023 08:30AM Mirum Pharmaceuticals Announces Positive Phase 3 RESTORE Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis
Sep 26, 2023 08:30AM Mirum Pharmaceuticals to Highlight LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting
Sep 21, 2023 08:30AM Mirum Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference
Sep 11, 2023 10:07AM Mirum Pharmaceuticals, Inc. (MIRM) Appoints Eric Bjerkholt as CFO
Sep 11, 2023 10:07AM Mirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer
Sep 8, 2023 11:30PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 6, 2023 08:30AM Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Aug 10, 2023 07:00PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 27, 2023 04:05PM Mirum Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023
Jul 25, 2023 08:33AM Mirum Pharmaceuticals's (MIRM) LIVMARLI Now Authorized in Canada for Cholestatic Pruritus in Patients with Alagille Syndrome
Jul 25, 2023 08:30AM Mirum’s LIVMARLI® Now Authorized in Canada for Cholestatic Pruritus in Patients with Alagille Syndrome
Jul 17, 2023 08:00AM Travere Therapeutics (TVTX) to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum (MIRM)
Jul 17, 2023 08:00AM Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals
View More Recent Stories View Older Stories